Related Industry Reports:
- Biomarker Technology Platforms for Cancer Diagnoses and Therapies
- Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
- Congestive Heart Failure: Major World Markets - Pharmaceutical Management
- R&D Trends: Sepsis - Improvements in clinical trial design and advances in biomarker research hold the key to a tailored approach to sepsis therapy
The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.
Immunobiology 2011 Nov 18; In press
Harutyunyan M, Christiansen M, Johansen JS, Køber L, Torp-Petersen C, Kastrup J
Department of Medicine B, The Heart Centre, Rigshospitalet, Copenhagen University Hospital and Faculty of Health Sciences, Denmark.
BACKGROUND: Despite progress in management of patients with heart failure (HF) these patients still have a poor prognosis. We tested the hypothesis whether the inflammatory biomarker YKL-40 alone or in combination with high-sensitivity C-reactive protein (hs-CRP) and/or N-terminal-pro-B natriuretic peptide (NT-proBNP) could be a new prognostic biomarker for all-cause mortality in patients with HF. METHODS AND RESULTS: A total of 717 of the 1000 patients with severe left ventricular systolic dysfunction included in the EchoCardiography and Heart Outcome Study were included in Denmark and had blood sample available for serum YKL-40 determination. Mean age of patients was 70 years, and 73% were male. During the 7 years follow-up period 458 patients died. Patients were categorised according to serum YKL-40 at entry into four quartiles: quartile I with median serum YKL-40=60μg/L (5-95% Confidence interval (CI): 30-82), quartile II: YKL-40=107μg/L (CI: 86-132), quartile III: YKL-40=169μg/L (CI: 142-221), and quartile IV: YKL-40=286μg/L (CI: 230-770). Hazard ratios for all-cause mortality were with quartile I as reference 1.33 (CI: 0.99-1.80), 1.35 (CI: 0.99-1.82), and 1.54 (CI: 1.14-2.08) for serum YKL-40 II to IV quartiles, respectively following multivariable adjustment for cardiovascular risk factors (age, left ventricular ejection fraction, gender, history of heart failure, ischemic heart disease, chronic pulmonary disease, diabetes mellitus, stroke, hypertension, NT-proBNP, hs-CRP, and renal function). CONCLUSION: Serum YKL-40 is significantly associated with all-cause mortality in patients with HF and could potentially be a new prognostic biomarker in these patients.